Niclas mouse model of AML by targeting primitive LSK and progenitor cells BCL-2 inhibition with ABT-737 prolongs survival in an NRAS / BCL-2

and Rose Ann Padua Dean W. Felsher, Anthony Whetton, Marika Pla, Robert West, Pierre Fenaux, Christine Chomienne Hervatin, Laure Sarda-Mantel, Marina Konopleva, Michael Andreeff, Andrea W. Tu, Alice C. Fan, Setterblad, Pierre de la Grange, Christophe Leboeuf, Anne Janin, Maria-Elena Noguera, Florence Stephanie Beurlet, Nader Omidvar, Petra Gorombei, Patricia Krief, Carole Le Pogam, Niclas mouse model of AML by targeting primitive LSK and progenitor cells BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2

[1]  P. Merlet,et al.  Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes. , 2013, Leukemia research.

[2]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[3]  G. Dellino,et al.  ABT-199: Taking Dead Aim at BCL-2 , 2013 .

[4]  Hao Xiong,et al.  Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Konopleva,et al.  MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex , 2012, Leukemia.

[6]  A. Roberts,et al.  Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. , 2011, Blood.

[7]  C. François,et al.  The Bcl-2 Homology Domain 3 (BH3) Mimetic ABT-737 Reveals the Dynamic Regulation of Bad, a Proapoptotic Protein of the Bcl-2 Family, by Bcl-xL , 2011, Molecular Pharmacology.

[8]  C. Rudin,et al.  Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Hallek,et al.  State of the art treatment of chronic lymphocytic leukaemia. , 2011, Blood reviews.

[10]  S. Rai,et al.  Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression , 2010, Cancer biology & therapy.

[11]  Gerard C Blobe,et al.  Roles for the type III TGF-beta receptor in human cancer. , 2010, Cellular signalling.

[12]  M. Minden,et al.  Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. , 2010, Leukemia research.

[13]  A. Roberts,et al.  The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs , 2010, Molecular Pharmacology.

[14]  D. Auboeuf,et al.  Splicing factor and exon profiling across human tissues , 2010, Nucleic acids research.

[15]  Yasodha Natkunam,et al.  Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens , 2009, Nature Medicine.

[16]  M. Butterworth,et al.  Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. , 2009, Blood.

[17]  M. Fujita,et al.  BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. , 2009, The Journal of investigative dermatology.

[18]  C. Scott,et al.  In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas , 2008, Proceedings of the National Academy of Sciences.

[19]  B. Friguet,et al.  Overexpression of Mitochondrial Methionine Sulfoxide Reductase B2 Protects Leukemia Cells from Oxidative Stress-induced Cell Death and Protein Damage* , 2008, Journal of Biological Chemistry.

[20]  C. Tse,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[21]  D. L. Wilburn,et al.  Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. , 2008, Cancer research.

[22]  M. Konopleva,et al.  Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway , 2008, Leukemia.

[23]  I. Weissman,et al.  BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. , 2007, Cancer research.

[24]  J. Cigudosa,et al.  DNA profiling by arrayCGH in acute myeloid leukemia and myelodysplastic syndromes , 2007, Cytogenetic and Genome Research.

[25]  G. Mufti,et al.  Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? , 2007, Cancer research.

[26]  C. Tse,et al.  Bcl-2 family proteins are essential for platelet survival , 2007, Cell Death and Differentiation.

[27]  P. Dent,et al.  Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. , 2007, Cancer research.

[28]  John Calvin Reed,et al.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.

[29]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[30]  B. Williams,et al.  Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. , 2005, Blood.

[31]  S. Flamant,et al.  Osteopontin is upregulated by BCR-ABL. , 2005, Biochemical and biophysical research communications.

[32]  Didier Auboeuf,et al.  FAST DB: a website resource for the study of the expression regulation of human gene products , 2005, Nucleic acids research.

[33]  T. Cotter,et al.  Bcr‐Abl regulates osteopontin transcription via Ras, PI‐3K, aPKC, Raf‐1, and MEK , 2005, Journal of leukocyte biology.

[34]  R. Craig,et al.  MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol , 2004, Oncogene.

[35]  G. Mufti,et al.  The Myelodysplastic Syndromes: A Matter of Life or Death , 2003, Acta Haematologica.

[36]  Qiang Yu,et al.  Bcl-2, via Its BH4 Domain, Blocks Apoptotic Signaling Mediated by Mitochondrial Ras* , 2003, The Journal of Biological Chemistry.

[37]  J. Downing,et al.  Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. , 2002, Blood.

[38]  H. Ackermann,et al.  The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia , 2002, Leukemia.

[39]  G. Mufti,et al.  The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. , 2000, Blood.

[40]  A. Yen,et al.  Regulation of MCL1 through a Serum Response Factor/Elk-1-mediated Mechanism Links Expression of a Viability-promoting Member of the BCL2 Family to the Induction of Hematopoietic Cell Differentiation* , 1999, The Journal of Biological Chemistry.

[41]  H. Shapiro,et al.  Accurate flow cytometric membrane potential measurement in bacteria using diethyloxacarbocyanine and a ratiometric technique. , 1999, Cytometry.

[42]  Parker,et al.  ‘Low‐risk’ myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro‐ versus anti‐apoptotic bcl‐2‐related proteins , 1998, British journal of haematology.

[43]  I. Weissman,et al.  The PEBP2betaMYH11 fusion created by Inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Chevret,et al.  RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up , 1998, Leukemia.

[45]  U. Maurer,et al.  High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  I. Weissman,et al.  bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages , 1994, The Journal of experimental medicine.